

THE PREMIER CDMO FOR TRANSDERMAL AND ORAL THIN FILM SOLUTIONS



COMPANY HIGHLIGHTS

- Founded in 1999
- Privately held by Gurnet Point Capital and Webster Equity Partners
- FDA/DEA registered facilities
- Transdermal/oral thin film experts
- Rx and OTC manufacturing
- 50+ issued patents

ADVANTAGES OF TRANSDERMAL DELIVERY

- Bypasses first pass metabolism
- Multiple day drug delivery
- Easier drug administration — no food effect, eliminates dosing/timing issues
- Potential for fewer side effects
- Avoids swallowing issues prevalent with certain diseases



Corium Innovations: Experienced Team Solves Complex Delivery Issues

Corium Innovations is a premier contract development and manufacturing organization (CDMO) that has a 25+ year history of successfully developing and manufacturing transdermal patches and oral thin film dosage forms to solve complex delivery problems that impact both patients and partners. The company maintains significant expertise in developing these unique product offerings that provide specific advantages to the patient experience and stands ready to assist partners in a broad array of film-based product needs from our FDA-registered, U.S. location in Grand Rapids, Michigan. With nearly 200,000 square feet of GMP facilities, we currently have annual capacity to produce over 200 million patches/films, including primary and secondary packaging options for a turnkey, readily saleable product cycle.

Corium Innovations has patents covering its transdermal delivery platforms that can be deployed to support your specific product needs.

Platform Technologies That Provide Innovative Delivery Solutions


Corplex® is our flagship matrix patch technology, which is the subject of several US and international patents. These fundamentally cover a broad range of **adhesive systems** and **bioavailability enhancement** approaches for small molecules. One such innovation driver is the **in-patch conversion** technology to transform salt forms of a drug into a higher bioavailable, free-base form of the molecule, resulting in higher levels of drug absorption across the skin.

HERE ARE SOME KEY FEATURES OF CORPLEX TECHNOLOGY

- ✓ Range of adhesive properties for aqueous and lipid delivery
- ✓ Improved drug bioavailability and high drug loading
- ✓ Excellent adhesion to both wet and dry surfaces
- ✓ Flexibility with natural skin movement
- ✓ Continuous delivery to 7 days from a single patch
- ✓ Patent protection

FIRST EVER 7 DAY TRANSDERMAL DELIVERY


Two unique TDS formulations show 7-day sustained drug profiles with lower C_{max} drug concentrations vs. a single oral dose of Zeposia®¹ in a parallel-design, human study (N=6 per arm).



¹ ZEPOSIA® (ozanimod) is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

Oral Thin Film Strips

Leveraging our existing manufacturing capabilities and equipment, Corium can manage the development and production of your next oral thin film (OTF) product. OTFs are thin, small (less than a postage stamp) biodegradable film strips containing drug substance that are designed primarily to be placed either sublingually or on the buccal mucosa (inside cheek). They are comprised of polymers that readily dissolve over a specified time period when placed in contact with saliva generated in the oral cavity. Corium Innovations has significant experience developing and manufacturing generic products in this dosage form.



ADVANTAGES OF ORAL THIN FILMS

- Avoids first-pass metabolism
- Higher drug bioavailability
- Potential to lower drug dose
- Fewer side effects possible
- Works with small molecules and peptides

PARTNERING FOR SUCCESS

Corium Innovations currently manufactures products for several partners across a multitude of therapeutic areas. Consider our team to support your products in the following areas:

- Feasibility and Clinical Supplies
- Co-development Programs
- Commercial Manufacturing
- Life Cycle Management

Manufacturing Excellence

Corium Innovations offers a full array of services and manufacturing capabilities from modern facilities in the United States. We are FDA-registered, DEA licensed (II-V) and ISO 9001 and ISO 13485 certified. Our team members have extensive knowledge of the chemistry, manufacturing and controls (CMC) for transdermal and oral thin film products and can assist in the following areas:

Development and Scale-up

- ✓ Formulation and process engineering
- ✓ Analytical method development and validation
- ✓ Phase I-III clinical trial supplies

Manufacturing and Testing

- ✓ Compounding and extrusion processing
- ✓ Coating, drying and laminating processes
- ✓ Die cutting and customization
- ✓ Physical and chemical testing
- ✓ Primary, secondary and tertiary packaging
- ✓ Contract GMP storage

Commercial Portfolio

Continued development efforts of high value brand and complex generic products for partnering.

Our Marketed Portfolio of Prescription and Consumer Products

Long-standing partnerships on well-known, FDA approved brand, generic and consumer products.

Teeth Whitening



Hypertension



Contraception



Key Performance Indicators



of shipments
On-Time and
In-Full (OTIF)



First time
through
quality

CONTACT INFORMATION

Please reach out to business development for further information:



Kevin Ostrander MS, MBA

Chief Business Officer

✉ kevin.ostrander@coriumintl.com or

✉ BizDev@coriumintl.com

☎ (908) 240-4486

🌐 coriuminv.com

